Kintara Therapeutics Shares Spike To Session High, Up 5% As Traders Circulate Zack’s Small Cap Research Note Showing $5.25 Price Target On Stock
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
Aegis Capital Maintains Buy on Kintara Therapeutics, Lowers Price Target to $5
Aegis Capital analyst Nathan Weinstein maintains Kintara Therapeutics (NASDAQ:KTRA) with a Buy and lowers the price target from $7 to $5.
Kintara Therapeutics: Q4 Earnings Insights
Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 28, 2021 at 08:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
Kintara Announces Closing Of $15M Offering Priced At Premium To Market; Shares Move Higher
Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to,
Benzinga’s Top Ratings Upgrades, Downgrades For September 28, 2021
Upgrades
For Bouygues (OTC:BOUYF), Jefferies upgraded the previous rating of Hold to Buy. At the moment, the stock has a 52-week-high of $43.06 and a 52-week-low of $33.96. Bouygues closed at $42.20 at the end of the last trading period.
HC Wainwright & Co. Initiates Coverage On Kintara Therapeutics with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Michael King initiates coverage on Kintara Therapeutics (NASDAQ:KTRA) with a Buy rating and announces Price Target of $6.